STING1 and neoplasm: MK‐2118, SB11285, GSK3745417, BMS‐986301, BI‐STING (BI 1387446), E7766, TAK‐676, SNX281, SYNB1891, BMS‐986301 are the STING agonizts in clinical development against different types of tumor and anticancer therapies [54].